- Home
- WLGS vs VIVS Comparison
WLGS vs VIVS Comparison
Compare WLGS & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLGS
- VIVS
- Stock Information
- Founded
- WLGS 1981
- VIVS 2007
- Country
- WLGS Hong Kong
- VIVS United States
- Employees
- WLGS N/A
- VIVS N/A
- Industry
- WLGS Engineering & Construction
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WLGS Consumer Discretionary
- VIVS Health Care
- Exchange
- WLGS Nasdaq
- VIVS Nasdaq
- Market Cap
- WLGS 4.4M
- VIVS 4.2M
- IPO Year
- WLGS 2023
- VIVS N/A
- Fundamental
- Price
- WLGS $0.04
- VIVS $1.80
- Analyst Decision
- WLGS
- VIVS
- Analyst Count
- WLGS 0
- VIVS 0
- Target Price
- WLGS N/A
- VIVS N/A
- AVG Volume (30 Days)
- WLGS 65.2M
- VIVS 62.5K
- Earning Date
- WLGS 08-14-2025
- VIVS 07-29-2025
- Dividend Yield
- WLGS N/A
- VIVS N/A
- EPS Growth
- WLGS N/A
- VIVS N/A
- EPS
- WLGS N/A
- VIVS N/A
- Revenue
- WLGS $3,951,649.00
- VIVS $144,000.00
- Revenue This Year
- WLGS N/A
- VIVS $42.38
- Revenue Next Year
- WLGS N/A
- VIVS $15.42
- P/E Ratio
- WLGS N/A
- VIVS N/A
- Revenue Growth
- WLGS N/A
- VIVS 32.11
- 52 Week Low
- WLGS $0.03
- VIVS $1.41
- 52 Week High
- WLGS $9.66
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- WLGS 31.65
- VIVS N/A
- Support Level
- WLGS $0.04
- VIVS N/A
- Resistance Level
- WLGS $0.08
- VIVS N/A
- Average True Range (ATR)
- WLGS 0.01
- VIVS 0.00
- MACD
- WLGS 0.01
- VIVS 0.00
- Stochastic Oscillator
- WLGS 23.18
- VIVS 0.00
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED. WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, water supply and sewage disposal systems, and site project management.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.